[DOT 2022] Optimized PAR2 assay using HT-29 PAR1 KO cells generated by CRISPR

[DOT 2022] Optimized PAR2 assay using HT-29 PAR1 KO cells generated by CRISPR
Version:
21223

File Name/Number:
DOT

Year:
2022

 

Protease-activated receptor 2 (PAR2) is an attractive target for the treatment of inflammation and cancer1. But screening and characterization of PAR2-targeting compounds is challenging, since most (if not all) cells also express PAR1.